以单胺氧化酶B为靶点的抗帕金森病药物的研究进展

Advances on monoamine oxidase B selective inhibitors as anti-Parkinson′s disease drugs

单胺氧化酶B(MAO-B)抑制剂包括可逆性抑制剂和不可逆性抑制剂,可用于帕金森病的治疗。不可逆性抑制剂的副作用较大,临床应用受到限制。寻求抑制性强、选择性高、毒副作用小的MAO-B可逆性抑制剂已成为药物化学研究的热点。本文回顾了近年对MAO-B抑制剂的研究进展,按照化学结构进行了分类阐述,并对其作用机制进行了概括性的总结。

Monoamine oxidase B inhibitors are mainly used to treat Parkinson＇s disease, which are classified into reversible and irreversible inhibitors. However, earlier MAO-B inhibitors are almost irreversible and are limited in clinical due to their side effects. Therefore, it has become a hot topic of academia to seek good efficiency, high selectivity and little side-effect MAO-B inhibitors in recent years. This article focuses on describing the development in recent years of MAO-B inhibitors which are classified by chemical structure, and summarizing their mechanism of inhibition.